

# HEMORRHOIDS

THIRD MOST COMMON OUTPATIENT GASTROINTESTINAL DIAGNOSIS<sup>1</sup>

Insights from Yang et. al., Burden and Cost of Outpatient Hemorrhoids in the United States Employer-Insured Population, 2014. Am J Gastroenterol. 2019;114(5):798-803

## ECONOMIC BURDEN

**\$2BN+**

spent annually on hemorrhoid diagnosis and treatment

SURGEON REFERRAL REMAINS COMMON

Despite the high expense and availability of an effective, painless and quick alternative



## BURDEN ON PATIENTS


MANY GO UNTREATED

Diagnosis without treatment accounts for 60%+ of the cost of hemorrhoid-related claims

OR

ARE PROVIDED SHORT-TERM SYMPTOM RELIEF WITHOUT TREATMENT OF CONDITION

52% of patients with a hemorrhoid-related claim are prescribed medication



98% of prescriptions contain hydrocortisone

Unproven in the long-term treatment of hemorrhoids<sup>2,3</sup>

**NOT IMPROVING PATIENT QUALITY OF LIFE**



HEMORRHOID TREATMENT IS EXPECTED TO INCREASE BY 23% OVER THE NEXT 20 YEARS

Symptomatic hemorrhoids are diagnosed in 18% of screening colonoscopies<sup>4</sup> BUT GIs only account for 8% of overall hemorrhoid diagnoses



**GASTROENTEROLOGISTS ARE IN A UNIQUE POSITION TO EFFECTIVELY DIAGNOSE AND PROVIDE PROVEN, DEFINITIVE AND COST-EFFECTIVE CARE FOR SYMPTOMATIC HEMORRHOIDS**

CRH has partnered with over 3,000 GIs across the US to help them diagnose and treat a variety of perianal issues, including symptomatic hemorrhoids

Speak with us to learn more  
info@crhmedcorp.com | 1.800.660.2153

CRH **ORegan System**<sup>®</sup>

Non-Surgical Hemorrhoid Treatment

Fast. Painless. Proven.